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The rapid scale-up of antiretroviral treatment (ART) 
programmes in sub-Saharan Africa has challenged the 
capacities of ART services to monitor and retain large 
numbers of patients within programmes effectively. 
Many ART clinics in sub-Saharan Africa now have to 
cope with patient complements of several thousands,1-3 
all of whom require monitoring and tracking. Initially, 
programme emphasis was placed on the maintenance 
of high levels of adherence to therapy, particularly be-
cause of the concerns of widespread viral resistance 
that could develop as a result of expanded access to ART 
in low- and middle-income countries (LMICs).4 The pub-
lic health approach to delivery of ART therefore recog-
nised the need for adherence strategies as an essential 
component of individual and programmatic treatment 
success.5 The South African ART guidelines included 
protocol provision for adherence counselling strategies 
within clinics.6 Despite initial scepticism, the feasibility 
of expanded access in LMICs has been justified by many 
early programmes reporting high levels of adherence7,8 
and viral suppression rates which were comparable with 
those achieved in industrialised settings.9 While these 
results were encouraging, they represented the success-
ful outcomes of individuals having been retained within 
the programmes, largely ignoring those individuals 
lost to each programme. However, overall programme 
performance and population impact may be more ac-
curately reflected by intention-to-treat (ITT) rather than 
on-treatment analysis (OTA). The differences between 
ITT and OTA results may be considerable, and a recent 
meta-analysis has highlighted that the loss to follow-up 
after initiating ART is a major problem facing large-scale 
ART roll-out programmes in sub-Saharan Africa.10
The result of a systematic review of attrition within sub-
Saharan African ART programmes on the proportion of 
adult patients remaining in care and on ART at 6 months 
or longer between 2000 and 2007 has been reported.10 
The analysis was based on data from 32 journal articles 
and conference abstracts describing 74 192 patients in 
non-research ART programmes in 13 countries. Reten-
tion was defined as the proportion of individuals known 
to be alive and receiving ART at the end of each fol-
low-up period, and included those transferred to other 
programmes. Attrition was defined as the proportion 
of those not retained, and was a composite measure 
comprising losses owing to death of 40%, losses to fol-
low-up of 56%, and discontinuation of ART within the 
programme of 4%. Weighted mean retention rates, as 
reported, were 79.1%, 75.0% and 61.6% at 6, 12 and 24 
months, respectively. Of those reporting 24 months of 
follow-up, the best programme retained 85%, and the 
worst retained 46%, of patients. Attrition was higher 
in those studies with shorter reporting periods, with 
monthly weighted mean attrition rates of 3.3%, 1.9% 
and 1.6% per month for studies reporting to 6, 12 and 
24 months, respectively. As those programmes report-
ing high attrition were least likely to provide data be-
yond 6 months, this was felt by the authors to indicate 
that overall patient retention had been overestimated 
in the published reports. The main conclusion was that 
overall attrition in African ART programmes was very 
high (40%) and was predominantly the result of loss 
to follow-up and, to a lesser degree, death. The authors 
concluded that there was a need for better patient trac-
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ing procedures, increased understanding of loss to fol-
low-up, and earlier initiation of ART in order to reduce 
mortality. As retention varied widely across programmes, 
it was felt that those programmes that had achieved 
higher retention rates might serve as models for future 
improvements.
cONVeNtIONaL data sOuRces
Conventional approaches to data collection are ‘doc-
tor-centred’, relying on patient information captured 
on data capture forms which are subsequently entered 
into a computerised database by a data entry clerk for 
subsequent use for programme evaluation (Fig. 1). More 
sophisticated versions incorporate direct entry of medi-
cal information into an electronic medical record (EMR) 
where the data are available for both patient care and 
programme evaluations. However, EMRs require compu-
ter networks and ongoing IT support which is frequently 
not available in many peripheral and community ART 
clinics. The rapid scale-up of ART to millions of patients, 
the scarcity of doctors and pharmacists, a poor com-
puter infrastructure and involvement of nurses and lay 
counsellors in patient care both inside and outside of 
formal clinics, compound the difficulties of data collec-
tion and collation. Furthermore, doctor visits are typi-
cally scheduled 6-monthly,6 which does not allow early 
detection of attrition from the programme as patients 
might have been off therapy for several months before 
being identified.
MINIMuM data ReQuIReMeNts FOR Itt aNaLyses
Data for programme evaluation of retention differs from 
that required for individual patient management and is 
therefore not just a consolidation of individual responses 
to ART. ITT analysis of programme performance necessi-
tates knowledge of the numbers of individuals initiat-
ing therapy, remaining on therapy, and lost (attrition) to 
the programme. Further classification of attrition into 
known deaths, transfers and remaining loss to follow-
up requires additional active follow-up procedures. Es-
tablishment of vital status may be difficult to achieve 
within a normal clinic, and may be better achieved in 
those services that have established interactions with 
patients at a community level.
PHaRMacy-Based data sOuRces
Pharmacy-based records have previously been reported 
to be a simple and effective population-level tool for 
monitoring adherence within scaling-up African HAART 
programmes.11 Pharmaceutical dispensing already 
requires the capturing of date information, patient 
identifiers such as age, and gender and contact details 
together with specifics of the prescription instructions 
from the health care provider. ART programmes may 
also easily add a requirement for justification of regi-
men changes classified into simple categories such as 
intolerance, toxicity or virological failure. If the date and 
time of patient receipt of ARVs could be captured, the 
pharmacy-based records could be expanded to capture 
programme retention data as well as adherence infor-
mation. Most of these data are required to be collected 
as part of routine pharmacy functioning in all treatment 
sites and can be made available for programme evalua-
tion without adding to the workload of busy clinics.
As an extension of the concept of using pharmacy infor-
mation as a programme evaluation tool, the intelligent 
dispensing of ART system (iDART) has been developed 
as a non-proprietary programme. iDART is a pharmacy 
application developed on open-source software that al-
lows dispensing of ART both on site and from a remote 
pharmacy. The system has been developed in response to 
a need to manage large numbers of patients on ART sim-
ply and effectively. The key benefits of the iDART system 
are accurate tracking of patient treatment and providing 
comprehensive patient treatment history. Operationally, 
iDART aids accurate ARV stock control management and 
faster pharmacy dispensing through faster processing. 
It reduces and identifies loss of ARVs, and it operates 
through clearly identifiable, multilingual bar-coded la-
bels which are created for each and every drug and pa-
tient package. iDART provides a pharmacy management 
tool incorporating stock-control, drug deliveries and 
drug-dispensing information designed to allow a central 
pharmacist to provide services to multiple satellite clin-
ics (Fig. 2). Demographic details, regimen dispensed and 
date and time of receipt of ART by the patient are cap-
tured without the need for additional data clerks (Table 
I). Standardised programme reports can be generated for 
funding agencies (e.g. PEPFAR) and health authorities 
(Fig. 3), together with updated lists of patients who have 
failed to pick up their prescriptions and who are default-
ing from the programme. The programme has already 
been successfully used in 7 large ART clinics in North 
West, Gauteng, Western Cape and Northern Cape prov-
inces and has been integrated with other data systems 
(e.g. EMR, lab-based) and the Western Cape provincial 
health record system (eKAPA). One of the most important 
idaRt systeM
Fig. 1. The data collection cycle.
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functions of iDART lies in the various reports that the 
software makes available. These range from basic stock 
control management and monitoring reports to specific 
patient defaulter lists, which facilitates easy manage-
ment and follow-up of patients. iDART also keeps the 
entire patient history of a patient in its database, pro-
viding accurate tracking of patients receiving treatment 
from ART sites (Fig. 4). The iDART system also allows the 
decanting of packages to remote clinics and dispensa-
ries that do not hold stock of ARVs; a central pharmacy 
prepares packages for patients belonging to remote clin-
ics and the system will trace the entire process until the 
patients collect their drugs. Feedback is then provided 
via the network or other data transfer systems to the 
central pharmacy to signal that the package was collect-
ed, and the pharmacist is then allowed to package drugs 
for the patient in the next month. Minimum system re-
quirements are a single computer, barcode printer and 
barcode reader. Data transfer can utilise a flash memory 
stick, cell phone, email or internet connection.
caPe tOWN idaRt cONFORMatION
The Cape Town central pharmacy receives and manages 
drug deliveries and supports peripheral clinics (Fig. 2). A 
single pharmacist and pharmacy assistant dispense ARVs 
to 2 peripheral clinics. Gugulethu is a busy doctor-based 
ARV clinic servicing >3 500 patients, which incorporates 
a nurse-led decanting clinic for patients established 
on stable ARVs. Masiphumelele is a smaller public-sec-
tor community polyclinic providing >800 patients with 
ARVs with both doctor- and nurse-led services. Gugu-
lethu and Masiphumelele are approximately 20 and 40 
kilometres distant from the pharmacy, respectively, with 
data transfer between peripheral site networks and cen-
tral database via a virtual private network (vpn).
sIZOPHILa cOMMuNIty adHeReNce PROGRaMMe
The Gugulethu ARV service is supported by a network of 
adherence counsellors who are recruited from the com-
munity, openly live with HIV and are trained and em-
ployed to carry out both clinic- and community-based 
services (Fig. 5). On any weekday, there are counsellors 
who report to the clinic in the morning and perform 
the clinic duties which include treatment readiness ses-
sions for new recruits, adherence trouble-shooting for 
established patients and day-to-day clinic operations. 
Fig. 2. The iDart system as applied to Gugulethu and 
Masiphumelele clinics.
idaRt inputs  Information captured  Outputs
ARVs delivered  ARVs in stock  Pharmacy stock control
ARV returns  ARVs dispensed  ARV regimens used
ARV expirations  
ARVs dispensed  
ARVs transferred to clinics 
Registration of patient  Demographic details  Programme reports
Date receipt of 1st ARVs Start date on ART  Individual adherence
Date of repeat ARVs  Duration of treatment  Individual retention
Failure to pick up ARVs  List of defaulters
taBLe I. INFORMatION caPtuRed FROM PHaRMacy aNd dIsPeNsING INPuts tO idaRt aNd INdIVIduaL 
PatIeNt aNd cONsOLIdated PROGRaMMe RePORt OutPuts
Fig. 3. An iDart programme report.
Fig. 4. An iDart clinic report.
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The majority of the team work daily from home, their 
clients having been assigned geographically. They at-
tend to home visits for new recruits as well as regular 
visits for defaulters and patients with adherence prob-
lems (red alert patients). Patients who adhere poorly, as 
indicated by pill counts, and patients who are not virally 
suppressed, are classified as ‘red alert’ and referred to 
their relevant counsellor for increased attention. A de-
faulters list is also generated from the iDART pharmacy 
system, based on missed pharmacy pick-up dates, and 
these patients are followed up by their counsellors. Ad-
herent patients are classified as ‘green’ patients and vis-
ited less frequently. They attend the clinic 2-monthly for 
new drug supply and are seen by a nurse practitioner or 
doctor every 4 months. Each counsellor is responsible for 
approximately 120 patients, of whom only the minority 
are ‘red alert’. Clinic-based activities ensure that patients 
are well informed about the need for treatment and 
programme adherence and, together with the red alert 
system, this ensures patient adherence, excellent viral 
suppression rates and thus sustained therapy options. 
However, it is the field-based activities of the counsel-
lors providing individualised support, home visits and 
regular follow-up that ensure ongoing adherence and 
excellent retention with reliable outcome data. iDART is 
an important trigger for the adherence/retention team 
that patients have defaulted treatment pick-up, result-
ing in immediate community follow-up by the relevant 
counsellor. This combination of clinic- and field-based 
counsellors together with iDART maintains excellent ad-
herence and viral suppression rates as well as remark-
ably low loss-to-follow-up rates in this large commu-
nity-based clinic in Gugulethu, Cape Town.
Pharmacy pick-up data by patients are well suited for 
identification of patients retained or those potentially 
lost to the programme. iDART is a flexible solution able 
to be implemented on a variety of IT platforms. Alone, 
it is a simple solution which can be implemented at pe-
ripheral clinic sites by pharmacy management, enabling 
standard report generation including early identification 
of programme losses, and it enables implementation of 
active community follow-up strategies.
As iDART has been developed on open source software 
which is free and requires no licence, the full pharmacy 
management system is available for implementation at 
any antiretroviral clinic and can be downloaded online at 
URL <http://www.cell-life.org/content/view/75/>.
REFERENCES
  1.  Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary 
care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296(7): 782-793.
  2.  Dalal RP, Macphail C, Mqhayi M, et al. Characteristics and outcomes of adult 
patients lost to follow-up at an antiretroviral treatment clinic in Johannesburg, 
South Africa. J Acquir Immune Defic Syndr 2008; 47(1): 101-107.
  3.  Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-
based HIV treatment service: programme performance over 3 consecutive years in 
Guguletu, South Africa. S Afr Med J 2006; 96(4): 315-320.
  4.  Harries AD, Nyanguku DS, Harries AD, et al. Preventing antiretroviral anarchy in 
Africa. Lancet 2001; 358: 410-414.
  5.  Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines 
for a public health approach. 2003 revision. Geneva: World Health Organization. 
http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf (accessed 10 April 
2008).
  6.  South African National Antiretroviral Treatment Guidelines. Pretoria: National 
Department of Health, 2004. http://www.hst.org.za/uploads/files/sa_ART_
Guidelines1.pdf (accessed 10 April 2008).
  7.  Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful 
antiretroviral therapy in South Africa. AIDS 2003; 17(9): 1369-1375.
  8.  Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-
Saharan Africa and North America. JAMA 2006; 296(6): 679-690.
  9.  Ivers LC, Kendrick D, Doucette K. Efficacy of anti-retroviral therapy programs in 
resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 
2005; 41: 217-224.
10.  Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in 
sub-Saharan Africa: A systematic review. Plos Med 2008; 4(10): e298.
11.  Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral 
therapy assessed by pharmacy claims predicts survival in HIV-infected South 
African adults. J Acquir Immune Defic Syndr 2006; 43(1): 78-84.
Fig. 5. Adherence counsellors are recruited from the 




pg44-48.indd   48 6/19/08   9:31:39 AM
